Humedics Reports 7.6 Billion KRW Operating Profit in Q2, Up 180% YoY

[Asia Economy Reporter Lee Gwanju] Humedix announced on the 16th that its operating profit on an individual basis for the second quarter increased by 180% compared to the same period last year, reaching 7.6 billion KRW. During the same period, sales amounted to 31.7 billion KRW, and net profit was 5.4 billion KRW, growing by 45% and 108%, respectively.

All business sectors, including aesthetics centered on Elravie filler and Riztox, active pharmaceutical ingredients, and contract manufacturing (CMO), achieved visible results. Thanks to social distancing measures and the lifting of outdoor mask mandates, as well as the reopening effect, the aesthetics business showed growth due to increased demand for fillers (Elravie Premier, Revoline) and toxins (Riztox), while the CMO business drove performance through increased sales of HA active pharmaceutical ingredients and higher orders for specialty pharmaceuticals and disposable eye drops.

Humedix plans to continue a positive trend in both external growth and profitability improvement in the second half of the year. They will strengthen aesthetic product lines by launching the ‘Elravie Premier Soft’ filler and plan to release PN joint injections and Korea’s first heparin sodium raw material DMF next year.

A Humedix official stated, “With improved operating conditions compared to last year, we achieved high growth in all areas, including our specialized aesthetics business and CMO business. In the second half, we will ensure the successful market establishment of newly launched businesses and continue the growth trend in performance.”

This content was produced with the assistance of AI translation services.